Mettler Toledo
MTD
$1490.76
+4.22%
Mettler-Toledo International is a precision instrument manufacturer supplying weighing, analytical, and process-control equipment to the life sciences (roughly 55% of sales), industrial (about 40%), and food retail (about 5%) end markets, with products spanning laboratory balances, pipettes, pH meters, titrators, thermal analysis systems, metal detectors, and X-ray inspection equipment. The company is the undisputed global leader in weighing instrumentation and controls more than half of the lab balance market, a position reinforced by a razor-and-blade consumables and service model, a direct global sales force, and switching costs embedded in regulated laboratory workflows. The current investor debate centers on whether Mettler-Toledo can sustain its premium multiple as instrument demand normalizes after the post-pandemic boom, with particular scrutiny on China (about 16% of sales) and broader industrial capex softness weighing on the order book. Offsetting this, the narrative has been bolstered by a sharp rebound in the shares since spring, a steady cadence of margin-accretive cost programs, and a Jefferies upgrade to Buy in March 2026 that signaled improving confidence in the earnings recovery trajectory.…
MTD
Mettler Toledo
$1490.76
Investment Opinion: Should I buy MTD Today?
The synthesized recommendation is Hold. Mettler-Toledo is a high-quality compounder with a wide moat, but the current valuation already reflects its strengths, and the analyst consensus of Hold with an average target of $1,452.50 implies only 4.3% upside. The core thesis is that the company will continue to deliver steady mid-single-digit revenue growth and margin expansion, but the premium multiple limits near-term returns.
The supporting evidence includes: 1) Revenue growth of 8.1% year over year in Q4 2025, with sequential improvement through the year; 2) Elite profitability, with gross margin of 58.0% and operating margin of 30.4%, well above industry averages; 3) Robust free cash flow of $848.6 million, which funds buybacks and supports the dividend-free capital return policy; 4) The forward PE of 26.9x is a premium to the market but justified by the company's quality and recurring revenue. However, the PEG ratio of 8.96 and EV/EBITDA of 24.9x indicate that the stock is not cheap relative to its growth rate.
The biggest risks that could invalidate the thesis are a slowdown in China or industrial demand, margin compression from cost inflation, and a de-rating of the premium multiple. The rating would upgrade to Buy if the stock pulls back to the $1,200-$1,250 range (implying a forward PE below 24x) or if revenue growth accelerates above 10%. It would downgrade to Sell if revenue growth decelerates below 5% or if operating margins fall below 28%. Relative to its own history (PE range of 25x-38x) and peers, the stock is fairly valued to slightly overvalued, trading in the upper-middle of its historical band.
Sign up to view all
MTD 12-Month Price Forecast
Mettler-Toledo is a high-quality franchise with durable competitive advantages, but the stock appears fairly valued at current levels. The forward PE of 26.9x already discounts the expected earnings recovery, and the consensus target implies limited upside. The company's exposure to cyclical industrial markets and China adds uncertainty, while the negative equity position reduces the margin of safety. I would upgrade to bullish if the stock pulls back to the $1,200-$1,250 range or if revenue growth accelerates above 10% with margin expansion. I would downgrade to bearish if revenue growth falls below 5% or if operating margins slip below 28%, signaling a deterioration in the core business.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mettler Toledo's 12-month outlook, with a consensus price target around $1457.50 and implied upside of -2.2% versus the current price.
Average Target
$1457.50
0 analysts
Implied Upside
-2.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$1200 - $1600
Analyst target range
Coverage is solid with 14 analysts, and the consensus is cautiously constructive rather than enthusiastic. The recommendation is Hold with a mean rating of 2.6 on a scale where 1 is Strong Buy and 5 is Strong Sell, and the average target price of $1,452.50 implies roughly 4.3% upside from the current $1,392.32. That modest implied return, combined with the Hold consensus, tells a story of a fairly valued quality compounder: analysts respect the franchise and the margin trajectory but see limited near-term multiple expansion from an already premium 33x trailing earnings base, and the consensus EPS estimate of $71.24 for the coming year is the linchpin of that math. The target range runs from $1,200 to $1,600, a spread of $400, or about 27.5% of the current price, which signals meaningful dispersion in views. The high target of $1,600 (roughly 15% above the current price) would require either multiple expansion back toward the upper end of the historical PE band or faster-than-expected earnings growth, potentially driven by a China recovery or accelerating lab demand; the low target of $1,200 (about 14% below current) prices in margin compression, industrial weakness, or a de-rating toward the low end of the historical PE range. Institutional ratings show a mild positive tilt in recent actions: Jefferies upgraded to Buy from Hold in March 2026, and the standing roster includes Buy/Overweight ratings from Citigroup, Stifel, Barclays, and Evercore ISI against Neutral/Equal Weight stances from JP Morgan, Morgan Stanley, and Wells Fargo. The absence of any Sell ratings and the recent upgrade suggest sentiment is improving off a low base, but the tight 4.3% upside to the average target and the wide $400 range mean the stock is best characterized as a high-quality hold rather than a high-conviction buy at current levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: MTD Investment Factors
The bull case rests on Mettler's elite margins, robust free cash flow, and dominant market position, which justify a premium multiple. The bear case centers on the stock's rich valuation (33x trailing PE, 25x EV/EBITDA), negative equity, and exposure to cyclical industrial and China demand, with analysts seeing limited upside. Currently, the bear evidence is slightly stronger because the valuation already prices in the earnings recovery, and the consensus Hold rating with only 4.3% upside suggests the risk-reward is balanced. The single most important tension is whether the expected 23% EPS growth materializes; if it does, the forward multiple compresses to a more palatable 26.9x, but any shortfall could trigger a de-rating toward the low end of the historical PE band.
Bullish
- Elite and expanding margins: Q4 2025 gross margin was 58.0% and operating margin 30.4%, with net margin climbing sequentially from 18.5% in Q1 to 25.3% in Q4. These are top-decile margins for the diagnostics and research tools industry, reflecting pricing power and operating leverage.
- Robust free cash flow generation: Trailing free cash flow is $848.6 million, and Q4 operating cash flow of $225.6 million comfortably covered $41.5 million of capex. This cash engine funds aggressive buybacks and supports the premium valuation.
- Market leadership with recurring revenue: Mettler controls more than 50% of the lab balance market, and its razor-and-blade model drives recurring consumables and service revenue. The life sciences segment (55% of sales) provides a stable, high-margin growth engine.
- Earnings recovery underway: Q4 2025 revenue rose 8.1% year over year to $1.13 billion, with each quarter of 2025 exceeding its 2024 counterpart. The forward PE of 26.9x versus trailing 33.1x implies the market expects roughly 23% EPS growth, consistent with the $71.24 consensus estimate.
Bearish
- Premium valuation leaves no margin for error: The trailing PE of 33.1x and EV/EBITDA of 24.9x are well above the 15-18x typical for instrumentation peers. The PEG ratio of 8.96 signals the multiple is not supported by near-term growth alone.
- Negative equity and leveraged balance sheet: Years of buybacks have pushed book equity below zero, rendering ROE (-36.8%) and debt-to-equity (-99.1) meaningless. With cash of just $66.9 million and a current ratio of 1.14, the balance sheet offers little cushion if earnings disappoint.
- China and industrial capex exposure: China represents about 16% of sales, and the industrial segment (40% of sales) is tied to broader capex cycles. Softness in these areas could pressure the order book and limit revenue growth to mid-single digits.
- Modest analyst upside and Hold consensus: The average target of $1,452.50 implies only 4.3% upside, and the consensus recommendation is Hold with a mean rating of 2.6. The wide target range of $1,200 to $1,600 reflects significant disagreement on the earnings trajectory.
MTD Technical Analysis
Mettler-Toledo is in a broad recovery uptrend that has stalled into consolidation. The stock is up 8.18% over the past year and 15.60% over six months, but the current price of $1,392.32 sits at roughly 73.6% of its 52-week range (low $1,023.05, high $1,525.17), meaning it has retraced a meaningful portion of its prior advance and is trading about 8.7% below the 52-week high. The 31.9% maximum drawdown over the past year confirms this has been a volatile, two-steps-forward-one-step-back recovery rather than a clean trend, and the position within the range argues against chasing strength at current levels while still leaving room to run if the uptrend reasserts. Recent momentum has turned negative and is diverging from the medium-term trend. The stock is down 2.30% over the past month and 1.28% on the latest session, yet it remains up 21.62% over three months, a classic deceleration pattern in which the powerful spring rally (from the May 13 low of $1,025.53 to the August 3 high of $1,445.00) is being digested. Relative strength tells the same story: MTD outperformed SPY by 19.62 percentage points over three months but lagged by 1.34 points over one month and 6.84 points over one year, suggesting the near-term pullback is a pause within a recovery rather than a fresh breakdown, though the failure to hold the $1,400 handle bears watching. Key levels are well defined. Support sits at the 52-week low of $1,023.05, with an intermediate shelf around $1,280-$1,290 (the September 9-10 lows of $1,290.36 and $1,280.58), while resistance is the 52-week high of $1,525.17 and the August swing high of $1,445.00. A breakout above $1,445 would confirm trend resumption toward the highs, whereas a breakdown below $1,280 would threaten a retest of the May lows; with a beta of 1.22, the stock is roughly 22% more volatile than the market, so position sizing should account for amplified moves in either direction, and the modest short ratio of 3.6 suggests no meaningful bearish crowding to fuel a squeeze.
Beta
1.22
1.22x market volatility
Max Drawdown
-31.9%
Largest decline past year
52-Week Range
$1023-$1525
Price range past year
Annual Return
+18.5%
Cumulative gain past year
| Period | MTD Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | +1.0% |
| 3m | +23.9% | +5.5% |
| 6m | +17.4% | +19.9% |
| 1y | +18.5% | +16.0% |
| ytd | +5.6% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MTD Fundamental Analysis
Revenue is growing at a healthy mid-single-digit pace with clear sequential momentum. Fourth-quarter 2025 revenue of $1.13 billion rose 8.1% year over year, and the quarterly progression through 2025 was consistently upward: $883.7 million in Q1, $983.2 million in Q2, $1.03 billion in Q3, and $1.13 billion in Q4, with each quarter exceeding its 2024 counterpart. Segment data shows laboratory products and services at $638.2 million and industrial products and services at $437.1 million, together representing the overwhelming majority of sales, with retail a small $54.4 million tail; the lab franchise is the growth engine and the industrial segment is the cyclical swing factor tied to broader capex. The trajectory implies the company is past the post-pandemic digestion phase, but the 8.1% growth rate is a far cry from the double-digit expansion of the boom years, so the investment case now rests more on margin and capital return than on top-line acceleration. Profitability is excellent and improving through the year. Q4 2025 net income was $285.8 million on a 25.3% net margin, with gross margin of 58.0% and operating margin of 30.4%, and the full-year progression shows steady expansion: net margin climbed from 18.5% in Q1 to 21.1% in Q3 to 25.3% in Q4, while operating margin rose from 24.8% to 30.4% over the same span. Gross margin has been remarkably stable in the 57.2%-58.0% band across all four quarters of 2025, indicating pricing power and a favorable mix rather than one-off gains. These are elite margins for the diagnostics and research tools industry, where high-50s gross and high-20s operating margins typically denote a wide-moat franchise, and the sequential margin ramp reflects both operating leverage on higher revenue and disciplined cost control (SG&A of $259.8 million in Q4 against $1.13 billion of revenue). The balance sheet is the one area requiring nuance. Free cash flow is robust at $848.6 million on a trailing basis, and Q4 operating cash flow of $225.6 million comfortably covered $41.5 million of capex, but the company carries a negative book equity position that renders ROE (-36.77%), debt-to-equity (-99.14), and P/B (-1,215.7) meaningless as standalone metrics; this is the artifact of years of aggressive share repurchases (roughly $218.7 million per quarter through 2025, including $143.7 million in Q4) that have shrunk the equity base below zero. Liquidity is adequate but not generous, with a current ratio of 1.14 and cash of just $66.9 million at year-end, and the cash flow-to-debt ratio of 0.096 alongside total-debt-to-capitalization above 100% underscores that the capital structure is deliberately leveraged. The key takeaway is that Mettler generates ample internal cash to fund capex and buybacks, but the negative equity means the balance sheet offers little cushion if earnings disappoint, making the durability of that $848.6 million FCF stream the critical fundamental anchor.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+8.1%
YoY Comparison
Gross Margin
58.1%
Latest Quarter
Free Cash Flow
$848648000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MTD Overvalued?
Because Mettler-Toledo is solidly profitable, the PE ratio is the appropriate primary metric. The stock trades at a trailing PE of 33.1x and a forward PE of 26.9x, and the 6.1-point gap between the two implies the market expects roughly 23% earnings growth over the next twelve months, consistent with the consensus EPS estimate of $71.24 versus the current run-rate. On the surface a 33x trailing multiple is rich, but the forward compression to 26.9x suggests the premium is at least partially underwritten by expected earnings recovery rather than pure multiple inflation. Relative to the broader market and the healthcare tools peer group, MTD screens as a premium asset. Its PS ratio of 7.14x and EV/Sales of 7.34x are elevated for a company growing revenue at 8.1%, and the EV/EBITDA of 24.9x sits well above the typical 15-18x range for diversified instrumentation peers, implying a premium of roughly 40-60% depending on the comparison set. The PEG ratio of 8.96 is the most striking outlier and signals that the current multiple is not supported by the near-term growth rate alone; investors are paying for quality, recurring revenue, and the durability of the franchise rather than for growth. The premium is defensible on margins (58.0% gross, 30.4% operating) and market leadership, but it leaves little room for execution error. Historically, MTD's own valuation band has been wide. The PE ratio troughed at 24.9x in Q4 2025 and peaked at 37.7x in Q1 2025, with the current 33.1x sitting in the upper-middle of that 25x-38x range, while the PS ratio of 7.14x is dramatically below the 24x-33x readings recorded in 2024-2025 historical data (a discrepancy that likely reflects a change in the share count or data methodology rather than a genuine 70% de-rating). Judged on PE, the stock is neither at a historical bargain nor at a bubble valuation; it is priced for continued margin expansion and mid-single-digit-plus growth, meaning the risk-reward is balanced and skewed by whether the earnings recovery meets the forward estimate embedded in the 26.9x forward multiple.
PE
33.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 25x~45x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.9x
Enterprise Value Multiple
Investment Risk Disclosure
Mettler-Toledo's financial risks stem from its deliberately leveraged capital structure and negative book equity. The company carries a debt-to-equity ratio of -99.1 and total-debt-to-capitalization above 100%, with only $66.9 million in cash and a current ratio of 1.14. While free cash flow of $848.6 million comfortably covers capex and buybacks, the negative equity means there is no balance sheet cushion if earnings decline. Additionally, the company's aggressive share repurchases (about $218.7 million per quarter) have shrunk equity, and any slowdown in cash generation could force a reduction in buybacks or increase leverage. The 8.1% revenue growth is healthy but far from the double-digit boom years, so the investment case relies heavily on margin expansion and capital return rather than top-line acceleration.
Market and competitive risks include valuation compression and cyclical demand softness. The stock trades at a trailing PE of 33.1x and EV/EBITDA of 24.9x, a 40-60% premium to diversified instrumentation peers, leaving little room for execution error. With a beta of 1.22, the shares are 22% more volatile than the market, amplifying downside in a risk-off environment. China accounts for about 16% of sales, and the industrial segment (40% of sales) is tied to broader capex cycles; a slowdown in these areas could pressure orders. The recent Jefferies upgrade and improving sentiment are positives, but the lack of any Sell ratings and the Hold consensus suggest that much of the good news is already priced in.
The worst-case scenario would involve a combination of slowing revenue growth, margin compression, and multiple de-rating. If China demand weakens further and industrial capex stalls, revenue growth could decelerate to low single digits, causing earnings to miss the $71.24 consensus estimate. This could trigger a de-rating toward the low end of the historical PE band (25x), implying a price near $1,200, which aligns with the analyst low target. From the current price of $1,392.32, that represents a downside of approximately 14%. A more severe scenario, such as a global recession, could push the stock toward its 52-week low of $1,023.05, a decline of about 26.5%. Given the 31.9% maximum drawdown over the past year, investors should be prepared for significant volatility.
FAQ
The key risks include: 1) Valuation risk: the premium multiple could compress if earnings growth disappoints, with the stock potentially falling to the analyst low target of $1,200 (-14%). 2) Cyclical risk: industrial and China exposure (40% and 16% of sales, respectively) makes revenue sensitive to capex cycles and geopolitical tensions. 3) Financial risk: negative book equity and a leveraged balance sheet (debt-to-equity -99.1) provide no cushion, and cash of only $66.9 million limits flexibility. 4) Competitive risk: while Mettler leads the lab balance market, competitors could pressure pricing in analytical instruments. The most severe risk is a global recession, which could push the stock toward its 52-week low of $1,023.05 (-26.5%).
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $1,525-$1,600, driven by a China recovery and multiple expansion. Base case (55% probability) targets $1,400-$1,500, assuming steady 6-8% revenue growth and EPS meeting the $71.24 consensus. Bear case (20% probability) targets $1,023-$1,200, reflecting a global slowdown and margin compression. The base case is most likely, with the stock trading in line with the analyst average target of $1,452.50. The key assumption is that revenue growth remains in the mid-single digits and operating margins stay above 30%.
MTD appears fairly valued to slightly overvalued. The trailing PE of 33.1x is in the upper-middle of its historical 25x-38x range, and the forward PE of 26.9x implies the market expects 23% earnings growth. The EV/EBITDA of 24.9x is a 40-60% premium to instrumentation peers, and the PEG ratio of 8.96 suggests the multiple is not supported by near-term growth alone. The market is paying a premium for Mettler's quality, recurring revenue, and margin profile, but this leaves little room for execution error. A more attractive entry point would be a forward PE below 24x, corresponding to a price near $1,250.
MTD is a high-quality company, but at the current price of $1,392.32, the risk-reward is balanced. The analyst consensus is Hold with an average target of $1,452.50, implying only 4.3% upside, while the stock trades at a premium 33.1x trailing PE. The biggest downside risk is a de-rating toward the 52-week low of $1,023.05, representing a 26.5% decline. For long-term investors comfortable with volatility (beta 1.22), it can be a core holding, but new buyers may want to wait for a pullback to the $1,200-$1,250 range to improve the margin of safety.
MTD is best suited for long-term investment. The company has a durable competitive advantage, a recurring revenue model, and a strong track record of margin expansion, making it a quality compounder. However, the stock is volatile (beta 1.22) and has experienced a 31.9% maximum drawdown in the past year, so short-term trading carries significant risk. With no dividend and a premium valuation, returns will depend on earnings growth and multiple stability. A minimum holding period of 3-5 years is recommended to ride out cyclical fluctuations and benefit from the company's long-term growth trajectory.
